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Background. Loss of bone density with androgen deprivation therapy for prostate cancer is well recognized. We assessed the eﬀects
of quarterly infusion of zoledronic acid on bone mineral density (BMD) and markers of bone turnover over a one-year period
in men receiving gonadotropin-releasing hormone analog (GnRH-a) for prostate cancer. Methods. 41 subjects were randomly
assigned to treatment with zoledronic acid (4mg) IV infusion or placebo every 3 months. The primary endpoint was the change
in the lumbar spine BMD after 12 months of treatment. Results. The change in vertebral BMD in the zoledronic acid group
(+7.93 ± 1.4%) was signiﬁcantly (P<. 05) greater than the change in the placebo group (+0.82 ± 1.7%) as was the change in
left femoral neck BMD (+5.05 ± 1.4% for the zoledronic acid group versus −0.48 ± 1.4% for the placebo group). The decrease in
biochemical markers of bone turnover was signiﬁcantly (P<. 05) greater in the zoledronic acid group compared to the placebo
group. Conclusion. Quarterly infusion of zoledronic acid for 1 year improved vertebral and left femoral neck BMD with a decrease
in bone turnover markers in men on GnRH-a treatment. Zoledronic acid treatment appears to be promising in men with low
BMD receiving GnRH-a treatment.
1.Introduction
Prostate cancer is the most common visceral malignancy
and the second leading cause of death from cancer in men
[1]. The dependence of prostate cancer on androgens has
led to the use of GnRH-a in the management of prostate
cancer [2, 3]. Androgen ablation using GnRH-a suppresses
testosterone production [3]. There are several studies show-
ing the eﬀect of GnRH-a treatment on bone mineral density
and bone metabolism in men with prostate cancer [4–6].
GnRH-a treatment results in reduction in bone mineral
density (BMD) and elevation in biochemical markers of
bone turnover. Bisphosphonates decrease bone resorption,
primarily by inhibiting osteoclast activity and proliferation
[7]. Zoledronic acid, the most potent intravenous bispho-
sphonate currently available, decreases bone turnover and
improves BMD in men [8–12]. We conducted a randomized,
double-blind, placebo controlled study to evaluate the eﬀect
ofzoledronicacidonBMDandbiochemicalmarkersofbone
turnover in men receiving androgen deprivation therapy for
prostate cancer.
2.MaterialsandMethods
2.1. Study Design. T h es t u d yw a sap r o s p e c t i v e ,r a n d o m -
ized, double-blinded, placebo controlled trial to determine
whether concomitant therapy with zoledronic acid could
prevent the progression and/or reverse the bone loss in
men with prostate cancer receiving GnRH-a treatment. The
primary objective was to evaluate whether such treatment2 Prostate Cancer
would prevent bone loss in the lumbar spine, and the
secondaryobjectivewastoevaluatetheeﬀectsoftreatmentin
the nondominant hip. The subjects were randomly assigned
to treatment with zoledronic acid 4mg IV infusion every
3 months or placebo over a study period of 12 months.
All subjects received oral calcium (elemental) 1000mg daily
and vitamin D 500IU daily. The study was approved by the
institutional review board (IRB) at the Northport Veterans
Aﬀairs Medical Center.
2.2. Inclusion Criteria. Patients with prostate cancer receiv-
ing regular injections of gonadotropin-releasing hormone
analogs (leuprolide or goserelin acetate) at the VA Medical
center in Northport, New York were screened with an initial
questionnaire ascertaining duration of therapy with GnRH-a
and subsequently underwent an initial BMD measurement.
Those patients with evidence of osteopenia or osteoporosis
were asked to participate in the study. Osteoporosis was
deﬁned as bone mineral density 2.5 standard deviations
below the mean (T-score < −2.5) and osteopenia as 1
standard deviation below the mean (T-score < −1.0).
2.3. Exclusion Criteria. The exclusion criteria were
(i) use of medication known to aﬀect bone mineral
density or bone metabolism (bisphosphonates, calci-
tonin, chronic steroid use, or estrogens),
(ii) medical history: disorders of bone metabolism
(hyperparathyroidism, Paget’s disease, or malab-
sorption syndrome (intestinal resection, pancreatic
insuﬃciency, or celiac sprue)),
(iii) hypogonadism other than biochemical castration
(e.g., congenital or surgical castration),
(iv) evidence of prostate cancer metastasis to bone (clin-
ical, biochemical, or radiological evidence of bone
metastasis); bone scan was not performed on all
patients prior to inclusion in the study,
(v) malignancy other than nonmelanoma skin cancer
(localized basal cell or squamous cell cancer),
(vi) serum creatinine >1.5mg/dl,
(vii) age >85 years.
2.4. Laboratory Evaluation. The following studies were per-
formed at baseline and at 3, 6, 9, and 12 months after
initiation of therapy.
(1) Markers of bone resorption: urinary N-telopeptide
(testing performed at Quest Laboratories).
(2) Markers of bone formation: serum osteocalcin and
serum bone-speciﬁc alkaline phosphatase (testing
performed at Quest Laboratories).
(3) The following studies were performed at baseline:
serum testosterone, serum intact PTH, serum 1,25
(OH)2 vitamin D, and serum 25 OH vitamin D
(testing performed at Quest Laboratories). Serum
creatinine was performed at Northport VA Medical
Center clinical chemistry Laboratory.
2.5. Bone Densitometry. Dual energy X-ray absorptiometry
(DXA) was used to measure the bone density of the lumbar
spine (L1–L4), left total hip, and left femoral neck using
the Hologic QDR-4500A X-ray Bone Densitometer. Quality
control of the machine was performed on a daily basis using
a spine phantom as per the guidelines of the company.
All scans were performed by the same technician in the
Nuclear Medicine Department at the VAMC Northport and
reviewed by the same radiologist as well as by the principal
investigator.
2.6. Sample Size. Sample size was based on comparisons
of BMD endpoint data (obtained at one year of followup)
between the zoledronic acid and placebo groups. To control
for group diﬀerences in baseline BMD levels, percent change
in BMD from baseline was the statistical outcome variable
comparison. Determination of required sample sizes per
group was based on a two-sided t-test with α = 0.05 and
a power of 90%. The standard deviation (SD) required for
sample size calculations was 0.082, as estimated from the
standard errors given by Ringe [13]. A similar estimate of
SD, 0.07, was obtained from the standard errors given by
Orwoll [14]. The ﬁrst estimate gives the more conservative
results. The research plan called for 30 patients per group
to have ample power (>90%) for statistically detecting a
group diﬀe r e n c e .T h i ss a m p l es i z ei so b t a i n e db a s e do nt h e
assumption that the true diﬀerence in the zoledronic acid
and placebo group means is 0.07 and the standard deviation
ofeachgroupis0.082.Inourstudy,duetoslowaccrualrates,
we closed the study before achieving this target sample size.
2.7. Randomization. The patients were screened between
August 2003 and March 2008 at the VAMC Northport. 42
patients consented to participate in the study. One patient
failed the screening. A random number generator randomly
partitioned the remaining 41 patients (via their medical
record numbers) into two groups (zoledronic acid and
placebo). Each group was identiﬁed with a code, known only
to the biostatistician and to the pharmacist who was not
involved in treating or evaluating the study participants and
who was responsible for preparing the active and placebo
treatments for the participants.
2.8. Statistical Analysis. The randomization of the partici-
pants into two groups prevented selection bias and resulted
in the two groups being similar with regard to baseline
clinical characteristics, including BMD levels. BMD mea-
surementsonpatientsweremadeattwotimepoints:baseline
and after 12 months of treatment. Percent changes of BMD
after 12 months of treatment were compared. The changes in
eachmeasure(BMDandT-score)betweenbaselineandafter
all infusions were compared between control and treatment
groups. A two-sided signiﬁcance level of 0.05 was used for a
two-sample t-test. The normality assumption was found to
be satisﬁed using Shapiro-Wilk test. The data analysis was
undertakenbyusingSASstatisticalsoftware(version9.1;SAS
Inc., Cary).Prostate Cancer 3
3. Results
3.1. Baseline and Followup. 21 patients were assigned to the
zoledronic acid group, and 20 patients were assigned to the
placebo group. 10 patients were excluded in the analysis of
BMD (4 in the zoledronic acid group and 6 in the placebo
group). In the zoledronic acid group, one patient died due
to metastasis from prostate carcinoma, and three patients
changed their mind after consenting and withdrew from
the study. In the placebo group, one patient died due to
metastasis from lung cancer, another patient was diagnosed
with prostate cancer metastasis to the spine during the study
and four patients did not show up for followup DXA scan
within a year after the last infusion. Total 31 patients were
included in the analysis of bone density. 17 patients (mean
age 74.7 years) received infusions of zoledronic acid and 14
patients (mean age 73.4 years) received placebo. All subjects
received 1 gram elemental calcium and 500 units of vitamin
D daily. All patients who received at least one infusion
were included in the analysis of BMD. Twenty-eight patients
received all four infusions.
3.2. Bone Mineral Density. There was no signiﬁcant dif-
ference in the baseline BMD measurements between the
two groups. The change in vertebral bone density in the
zoledronic acid group (+7.93 ± 1.4%) was signiﬁcantly
(P < .05) greater than the change in the placebo group
(+0.82 ± 1.7%) as was the change in left femoral neck bone
density (+5.05 ± 1.4% for the zoledronic acid group versus
−0.48 ± 1.4% for the placebo group). Left total hip BMD
increased, 2.27 ± 0.92%, in the zoledronic acid group but
this change was not signiﬁcantly diﬀerent from the placebo
group (Table 1). In the zoledronic acid group, one patient
had hardware in the spine, and one patient had left hip
replacement. Spine BMD in the patient with hardware in
the spine and left hip BMD in the patient with left hip
replacement were not included in the analysis. The change
in vertebral T-score in the zoledronic acid group (0.65 ±
0.11) was signiﬁcantly (P < .05) greater than the change in
the placebo group (−0.02 ± 0.14) as was the change in left
f e m o r a ln e c kT - s c o r e( 0 . 1 6± 0.07 for the zoledronic acid
group versus −0.04 ± 0.07 for the placebo group) as shown
in Figure 1.
3.3. Biochemical Markers of Bone Turnover. There were no
signiﬁcant diﬀerences in the baseline characteristics (age,
serum creatinine, serum calcium, testosterone, parathyroid
hormone, 25-hydroxy vitamin D, 1,25-dihydroxy vitamin D,
and biochemical markers of bone turnover) between the two
groups. All patients in the two groups were hypogonadal
with baseline testosterone levels less than 50ng/dl. The levels
of urine N-telopeptide, serum osteocalcin, and serum bone-
speciﬁc alkaline phosphatase (BSAP) were 49 ± 6.6%, 51.6 ±
6.1%, and 38.8 ± 7.5%, lower than baseline in the zoledronic
acid group (Table 2). These changes were signiﬁcantly lower
than the percent changes in placebo at signiﬁcance level 0.05.
Figure 2 compares the biochemical marker levels between
zoledronic acid and placebo groups at each time point.
Urine N-telopeptide (NTX), osteocalcin, and BSAP show
signiﬁcant diﬀerence between the two groups at 3, 6, and 9
months (P-value < .05).
3.4. Adverse Events. Zoledronic acid treatment was well
tolerated by most subjects except for one subject who devel-
oped atrial ﬁbrillation and another subject who developed
reversible acute renal failure in the study. Both subjects
received zoledronic acid. There were no cases of osteonecro-
sis of the jaw.
4. Discussion
In our study, zoledronic acid was eﬀective in preventing
bone loss and improving markers of bone resorption in
prostate cancer patients with low bone mineral density
receiving androgen deprivation therapy. The treatment was
well tolerated by most of the patients except one subject who
developed atrial ﬁbrillation 8 weeks after the ﬁrst dose of
zoledronic acid and another subject who developed acute
renal failure following a bout of acute enteritis while also
taking ibuprofen. The subject’s renal function gradually
returnedtobaseline.Thesesubjectswereincluded inanalysis
of BMD. The subject with atrial ﬁbrillation was included
in analysis of bone biomarkers while the subject with acute
renal failure was excluded in the analysis of bone biomarkers.
Our study results are consistent with previous studies
showing a beneﬁcial eﬀect of zoledronic acid on bone
mineral density done in men with prostate cancer treated
with hormone deprivation therapy [8–12]. In our study, we
evaluated the eﬀect of quarterly infusion of zoledronic acid
on bone mineral density in patients with non-metastatic
prostate cancer similar to studies reported by Smith et al.
[8] and Ryan et al. [9]. In our study, the change in vertebral
bone density in the zoledronic acid group (7.93 ± 1.4%) was
signiﬁcantly (P < .05) greater than the change in the placebo
group (0.82 ± 1.7%) as was the change in left femoral neck
bone density ((5.05 ± 1.4%) for the zoledronic acid group
versus (−0.48 ± 1.4%) for the placebo group).
Smith et al. [8] reported that mean bone mineral density
in the lumbar spine increased by 5.6% in men receiving
zoledronic acid and decreased by 2.2% in the placebo group
(meandiﬀerence7.8%,P< .001);patientsintheirstudywere
na¨ ıve to androgen deprivation therapy. Ryan and coworkers
[9] found that zoledronic acid increased lumbar spine,
femoralneck,andtotalhipBMDyearlyby6.7%(P < .0001),
3.6% (P = .0004), and 3.8% (P < .0001), signiﬁcantly greater
than placebo.
Israeli et al. [10] evaluated the eﬀect of quarterly infusion
of zoledronic acid on bone mineral density in patients with
locally advanced prostate cancer during the ﬁrst year of
androgen deprivation therapy. At week 52, the least squares
mean BMD percentage diﬀerences of 6.7% for the lumbar
spine and 3.7% for the total hip were signiﬁcantly greater
in the zoledronic acid group in comparison to the placebo
group (P < .0001).
Michaelsonetal.[11]andSatohetal.[12]bothevaluated
the eﬀect of yearly infusion of zoledronic acid on bone4 Prostate Cancer
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Figure 1: BMD and T-score measures at baseline and ﬁnal.
Table 1: Comparison of mean ± SE percent change in BMD from baseline to ﬁnal in BMD (gm/cm2) between two groups. A two-sided
signiﬁcance level of 0.05 is used for a two-sample t-test.
Placebo Zoledronic acid P-value
L1-L4 vertebrae
N 14 16
.003 Baseline 0.946 (0.052) 0.928 (0.030)
Final 0.944 (0.042) 1.000 (0.031)
Mean % change +0.82 (1.7) +7.93 (1.4)
Left total hip
N 13 16
.278 Baseline 0.888 (0.027) 0.868 (0.023)
Final 0.893 (0.024) 0.889 (0.029)
Mean % change +0.71 (1.1) +2.27 (0.92)
Left femoral neck
N 13 16
.009 Baseline 0.718 (0.019) 0.690 (0.029)
Final 0.713 (0.017) 0.724 (0.030)
Mean % change −0.48 (1.4) +5.05 (1.4)
mineral density in patients with prostate cancer. In the Satoh
e ta l .s t u d y ,p a t i e n t sw e r en a ¨ ıve to androgen deprivation
therapy and had metastases to bone. Michaelson et al. found
that the BMD in the lumbar spine increased by 4.0% ± 1.0%
(mean ± SE, P < .001) and femoral neck BMD increased by
2.0%± 0.6% in men given zoledronic acid (P = .06) whereas
Satoh et al. reported that the mean BMD in the lumbar
spineincreasedby3.5% ±0.8%(P = .004)andfemoralneck
BMD increased by 5.1% ± 1.3% (P = .0393) yearly in men
assigned to zoledronic acid. Both these studies suggest that
once-yearly infusion of zoledronic acid might be suﬃcient in
this group of patients [11, 12].
All three biochemical markers of bone turnover (urine
N-telopeptide, serum osteocalcin, and serum BSAP) in ourProstate Cancer 5
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Figure 2: Comparison of biomarker levels between that two groups at each time point.6 Prostate Cancer
Table 2: Comparison of mean and SE percent change in biochemical markers of bone turnover from baseline to ﬁnal between the two
groups. Signiﬁcant diﬀerences were observed in urine NTX, osteocalcin, and BSAP.
Placebo Zoledronic acid P-value
Serum creatinine (mg/dL)
N 13 15
.58 Baseline 0.969 (0.073) 0.960 (0.050)
Final 1.008 (0.055) 0.993 (0.055)
Mean % change +9.8 (10) +3.7 (2.8)
Serum calcium (mg/dL)
N 13 15
.45 Baseline 9.654 (0.12) 9.267 (0.15)
Final 9.515 (0.11) 9.247 (0.11)
Mean % change −1.36 (1.1) −0.02 (1.4)
Urine NTX Collagen cross-linked urine
(nmol BCE/mmol creatinine)
N 13 14
.022∗ Baseline 38.2 (4.9) 41.4 (5.3)
Final 40.4 (4.0) 18.8 (2.3)
Mean % change +32 (30) −49 (6.6)
Serum osteocalcin (ng/mL)
N 13 14
.0003∗ Baseline 23.7 (1.5) 25.2 (2.5)
Final 18.6 (1.6) 11.6 (1.4)
Mean % change −22.1 (3.5) −51.6 (6.1)
Serum bone-speciﬁc alkaline phosphatase
(BSAP) (mcg/L)
N 13 15
.002∗ Baseline 15.5 (2.0) 14.3 (1.3)
Final 14.9 (2.0) 8.1 (0.9)
Mean % change −2.0 (7.3) −38.8 (7.5)
∗Signiﬁcant at level 0.05. Standard error follows mean in parentheses.
study decreased signiﬁcantly (P < .05) in the zoledronic acid
group compared to the placebo group as in previous studies
[9–11]. There was signiﬁcant decrease in serum calcium
after the ﬁrst infusion of zoledronic acid which returned to
baseline at subsequent infusions. There was no signiﬁcant
change in serum creatinine level in either group.
Saad et al. [15] studied the eﬀect of zoledronic acid on
skeletal complications in prostate cancer patients with bone
metastases. In their study, zoledronic acid at 4mg or 8mg
given every 3 weeks reduced skeletal-related events (deﬁned
as pathologic bone fractures (vertebral or nonvertebral),
spinal cord compression, bone surgery, radiation therapy to
bone, or a change of antineoplastic therapy to treat bone
pain) and increased the median time to ﬁrst skeletal-related
event in prostate cancer patients with bone metastases. We
did not evaluate skeletal-related events in our study.
Our study has limitations. The sample size was small.
We studied only one dosing regimen, and the study duration
was only one year. The study was not powered to assess the
impact on skeletal-related events. We think studies of longer
duration and with diﬀerent dosing regimens are needed to
evaluate long-term safety and eﬃcacy of zoledronic acid in
these patients and its impact on skeletal-related events.
5. Conclusion
Quarterly infusion of zoledronic acid for 1 year improved
vertebral and left femoral neck bone mineral density with
a decrease in bone turnover markers in men receiving
androgen deprivation therapy with GnRH-a. Our study adds
to the previously reported evidence that zoledronic acid
should be considered as a treatment option in men with low
bone mineral density receiving GnRH-a.
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